Cargando…

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race

Detalles Bibliográficos
Autores principales:	García-Muñoz, Ricardo, Anton-Remirez, Judit, Nájera, María Josefa, Gutierrez-Gamarra, Elena, Peralta, Raisa, Feliu, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426171/ https://www.ncbi.nlm.nih.gov/pubmed/30906570 http://dx.doi.org/10.4155/fsoa-2018-0122

Ejemplares similares

The Tortoise and the Hare: Guinea Worm, Polio and the Race to Eradication
por: Sutton, Brett, et al.
Publicado: (2015)

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Signaling with tortoise and hare
por: LeBrasseur, Nicole
Publicado: (2005)

The tortoise and the hare revisited
por: Kononenko, Natalia L, et al.
Publicado: (2013)

The hare and the tortoise : culture, biology, and human nature /
por: Barash, David P.

Tortoise puts brake on hare
por: Wells, William A.
Publicado: (2006)

Malaria Control: Tortoises and Hares
por: Meshnick, Steven R.
Publicado: (2015)

Targeting the IGF-1R: The Tale of the Tortoise and the Hare
por: Crudden, Caitrin, et al.
Publicado: (2015)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Dynamics of nutrient uptake strategies: lessons from the tortoise and the hare
por: Menge, Duncan N. L., et al.
Publicado: (2011)

Survival Analysis and Interpretation of Time-to-Event Data: The Tortoise and the Hare
por: Schober, Patrick, et al.
Publicado: (2018)

Evolutionary Genetics of Mycobacterium Tuberculosis and HIV-1: “The Tortoise and the Hare”
por: Santos-Pereira, Ana, et al.
Publicado: (2021)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

A rare cause of narrow QRS complex tachycardia: the tortoise and the hare
por: Yap, S. C.
Publicado: (2022)

A rare cause of narrow QRS complex tachycardia: the tortoise and the hare
por: Yap, S. C.
Publicado: (2022)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Unicorn, Hare, or Tortoise? Using Machine Learning to Predict Working Memory Training Performance
por: Feng, Yi, et al.
Publicado: (2023)

Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development
por: Poland, Gregory A.
Publicado: (2020)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Obinutuzumab/rituximab: Decreased platelet count and chronic COVID-19 pneumonia: case report
Publicado: (2020)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
por: Kvacskay, Peter, et al.
Publicado: (2022)

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
por: Reddy, Venkat R, et al.
Publicado: (2021)

Serology-based therapeutic strategy in SARS-CoV-2-infected patients
por: Garcia-Muñoz, Ricardo, et al.
Publicado: (2021)

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
por: Lachowiez, Curtis, et al.
Publicado: (2017)

Tortoise or Hare? The Associations between Physical Activity Volume and Intensity Distribution and the Risk of All-Cause Mortality: A Large Prospective Analysis of the UK Biobank
por: Salway, Ruth, et al.
Publicado: (2023)

Gift of the Tortoise/
por: Ladysmith abalsck Manbazo

The Tortoise and the Hut
por: Potter, Polyxeni
Publicado: (2011)

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
por: Seymour, John F., et al.
Publicado: (2019)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
por: Hong, Xiaonan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jr2f82otluih6ejbigbgkes9p3